DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ryu, Ye-Lim | ko |
dc.contributor.author | Jung, Kyung Hee | ko |
dc.contributor.author | Son, Mi Kwon | ko |
dc.contributor.author | Yan, Hong Hua | ko |
dc.contributor.author | Kim, Soo Jung | ko |
dc.contributor.author | Shin, Sang Hye | ko |
dc.contributor.author | Hong, Sungwoo | ko |
dc.contributor.author | Hong, Soon-Sun | ko |
dc.date.accessioned | 2014-12-16T01:08:00Z | - |
dc.date.available | 2014-12-16T01:08:00Z | - |
dc.date.created | 2014-10-27 | - |
dc.date.created | 2014-10-27 | - |
dc.date.issued | 2014-10 | - |
dc.identifier.citation | CANCER LETTERS, v.353, no.1, pp.68 - 77 | - |
dc.identifier.issn | 0304-3835 | - |
dc.identifier.uri | http://hdl.handle.net/10203/192757 | - |
dc.description.abstract | Pancreatic cancer is known to have low 5-year survival rate and poor response to treatment. In this study, we synthesized HS-527, a new PI3-kinase inhibitor, and investigated not only its anticancer activity, but also its mechanism of action in pancreatic cancer cells. HS-527 had higher specificity for PI3K than other kinases and inhibited PI3K/Akt signaling pathway by down-regulating Akt and P70S6K. And HS-527 inhibited the cell growth and proliferation of the pancreatic cancer in a time- and dose-dependent manner, with greater activity than gemcitabine. Even HS-527 showed lower cytotoxicity than gemcitabine in normal cells. When treated with HS-527, the cancer cells appeared apoptotic, increasing the expression of cleaved PARP, cleaved caspase-3, and Bax. Furthermore, HS-527 showed an anti-angiogenic activity by decreasing the expression of HIF-1 alpha, and VEGF, and inhibited the migration of endothelial cells, and the formation of new blood vessel in mouse Matrigel plug assay. In this study, we found that HS-527 showed anti-cancer activity through an inhibition of the PI3K/Akt pathway in pancreatic cancer cells, suggesting that HS-527 could be used as a promising therapeutic agent for pancreatic cancer. | - |
dc.language | English | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.subject | PI3K PATHWAY | - |
dc.subject | ANGIOGENESIS | - |
dc.subject | APOPTOSIS | - |
dc.subject | THERAPY | - |
dc.subject | AKT | - |
dc.subject | GEMCITABINE | - |
dc.subject | RESISTANCE | - |
dc.subject | DEATH | - |
dc.subject | STATISTICS | - |
dc.subject | SURVIVAL | - |
dc.title | Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells | - |
dc.type | Article | - |
dc.identifier.wosid | 000342268800009 | - |
dc.identifier.scopusid | 2-s2.0-84908373267 | - |
dc.type.rims | ART | - |
dc.citation.volume | 353 | - |
dc.citation.issue | 1 | - |
dc.citation.beginningpage | 68 | - |
dc.citation.endingpage | 77 | - |
dc.citation.publicationname | CANCER LETTERS | - |
dc.identifier.doi | 10.1016/j.canlet.2014.07.001 | - |
dc.contributor.localauthor | Hong, Sungwoo | - |
dc.contributor.nonIdAuthor | Ryu, Ye-Lim | - |
dc.contributor.nonIdAuthor | Jung, Kyung Hee | - |
dc.contributor.nonIdAuthor | Son, Mi Kwon | - |
dc.contributor.nonIdAuthor | Yan, Hong Hua | - |
dc.contributor.nonIdAuthor | Kim, Soo Jung | - |
dc.contributor.nonIdAuthor | Hong, Soon-Sun | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | PI3K | - |
dc.subject.keywordAuthor | HS-527 | - |
dc.subject.keywordAuthor | Pancreatic cancer | - |
dc.subject.keywordAuthor | Apoptosis | - |
dc.subject.keywordAuthor | Angiogenesis | - |
dc.subject.keywordPlus | PI3K PATHWAY | - |
dc.subject.keywordPlus | ANGIOGENESIS | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | AKT | - |
dc.subject.keywordPlus | GEMCITABINE | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | DEATH | - |
dc.subject.keywordPlus | STATISTICS | - |
dc.subject.keywordPlus | SURVIVAL | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.